Drugs / GSK3003896A
last change Mar 2015 re-read 2 minutes ago

GSK3003896A

Vaccine

Developed for
respiratory syncytial virus infectious disease
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01905215 Jul 2013 → Apr 2014 respiratory syncytial virus infectious disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK3003896A ClinicalTrials.gov intervention name — accepted as the source's own label NCT01905215
Modality Vaccine “RSV vaccine GSK3003896A (formulation 4)” NCT01905215
Route Intramuscular Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule” NCT01905215